Summary:
Join the Alopecia Study to Help Advance Research for Alopecia Areata.
Alopecia areata is a common autoimmune skin disease, causing hair loss on the face, scalp, and sometimes on other areas of the body. Numerous factors contribute to the development of this complex condition. This condition happens when your immune system mistakes the normal cells in your body as foreign invaders and attacks these cells. Experts aren’t exactly sure what “triggers” the immune system to attack healthy hair follicles when people have alopecia areata, or even if these triggers first happen inside the body (from a virus or bacteria), outside the body (environmental) or if it’s a combination of both. Because of this, there is a need for further information into this condition.
About the IM011134 Alopecia Study
The IM011134 study is testing an investigational drug called deucravacitinib (also known as the “study drug”) in people with alopecia areata. The purpose of the study is to learn whether the study drug is safe and effective at different dose levels.
Am I Eligible for the IM011134 Alopecia Study?
To join the study, you must meet the study eligibility criteria. You may be eligible to participate in the study if you meet the following criteria:
- Are 18 to 65 years of age
- Have been diagnosed with alopecia areata for at least 6 months
- Have been experiencing your current episode of scalp hair loss for at least 6 months with no significant spontaneous regrowth over the last 6 months
The study doctor will also check additional eligibility requirements.